www.fgks.org   »   [go: up one dir, main page]

Warning: The NCBI web site requires JavaScript to function. more...

Format

Send to

Choose Destination
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):921-925. doi: 10.1002/pds.4569. Epub 2018 Jun 3.

Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.

Author information

1
Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
2
Health Partners Institute, Minneapolis, MN, USA.
3
Kaiser Permanente Southern California, Pasadena, CA, USA.
4
Kaiser Permanente Northern California, Oakland, CA, USA.
5
Marshfield Clinic Research Institute, Marshfield, WI, USA.
6
Kaiser Permanente Northwest, Portland, OR, USA.
7
Kaiser Permanente Colorado, Denver, CO, USA.
8
Centers for Disease Control and Prevention, Atlanta, GA, USA.

Abstract

In light of waning immunity to pertussis following receipt of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine, maintaining protection may require repeated Tdap vaccination. We evaluated the safety of repeated doses of tetanus-containing vaccine in 68 915 nonpregnant adolescents and adults in the Vaccine Safety Datalink population who had received an initial dose of Tdap. Compared with 7521 subjects who received a subsequent dose of tetanus toxoid, reduced diphtheria (Td) vaccine, the 61 394 subjects who received a subsequent dose of Tdap did not have significantly elevated risk of medical visits for seizure, cranial nerve disorders, limb swelling, pain in limb, cellulitis, paralytic syndromes, or encephalopathy/encephalitis/meningitis. These results suggest that repeated Tdap vaccination has acceptable safety relative to Tdap vaccination followed by Td vaccination.

KEYWORDS:

pharmacoepidemiology; vaccination; whooping cough

PMID:
29862604
PMCID:
PMC6541919
[Available on 2019-08-01]
DOI:
10.1002/pds.4569

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center